BLA 125084 · Imclone
Erbitux
Cetuximab · Intravenous · Epidermal Growth Factor Receptor Antagonist
NovelAccelerated approvalPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Sep 24, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2004
Feb 12, 2004
Approved uses
9
Original approval plus efficacy supplements
Registered trials
1,124
144 Phase 3, 158 recruiting
FAERS reports
31,703
27,066 serious, 4,267 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: INFUSION REACTIONS and CARDIOPULMONARY ARREST Infusion Reactions: ERBITUX can cause serious and fatal infusion reactions [see Warnings and Precautions ( 5.1 ), Adverse Reactions ( 6 )] . Immediately interrupt and permanently discontinue ERBITUX for serious infusion reactions [see Dosage and Administration ( 2.5 )] . Cardiopulmonary Arrest: Cardiopulmonary arrest or sudden death occurred in patients with squamous cell carcinoma of the head and neck receiving ERBITUX with radiation therapy or a cetuximab product with platinum-based therapy and fluorouracil. Monitor serum electrolytes, including serum magnesium, potassium, and calcium, during and after ERBITUX administration [see Warnings and Precautions ( 5.2 , 5.6 )] . WARNING: INFUSION REACTIONS and CARDIOPULMONARY ARREST See full prescribing information for complete boxed warning. ERBITUX can cause serious and fatal infusion...
What it is approved for
From the label in effect Apr 16, 2026.
ERBITUX ® is an epidermal growth factor receptor (EGFR) antagonist indicated for treatment of: Head and Neck Cancer Locally or regionally advanced squamous cell carcinoma of the head and neck in combination with radiation therapy. ( 1.1 , 14.1 ) Recurrent locoregional disease or metastatic squamous cell carcinoma of the head and neck in combination with platinum-based therapy with fluorouracil. ( 1.1 , 14.1 ) Recurrent or metastatic squamous cell carcinoma of the head and neck progressing after platinum-based therapy. ( 1.1 , 14.1 ) Colorectal Cancer K-Ras wild-type, EGFR-expressing, metastatic colorectal cancer as determined by an FDA-approved test in combination with FOLFIRI for first-line treatment, in combination with irinotecan in patients who are refractory to irinotecan-based chemotherapy, as a single-agent in patients who have failed oxaliplatin- and irinotecan-based chemotherapy or who are intolerant to irinotecan. ( 1.2 , 5.7 , 12.1 , 14.2 ) Limitations of Use: ERBITUX is not indicated for treatment of Ras-mutant colorectal cancer or when the results of the Ras mutation tests are unknown. ( 5.7 ) BRAF V600E Mutation-Positive Metastatic Colorectal Cancer (CRC) in combination with encorafenib, for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, as detected by an FDA-approved test, after prior therapy. ( 1.3 ) 1.1 Squamous Cell Carcinoma of the Head and Neck (SCCHN) ERBITUX ® is indicated: in combination with radiation therapy for the initial treatment of locally or regionally advanced squamous cell carcinoma of the head and neck (SCCHN). in combination with platinum-based therapy with fluorouracil for the first-line treatment of patients with recurrent locoregional disease or metastatic SCCHN. as a...
Mechanism: The epidermal growth factor receptor (EGFR, HER1, c-ErbB-1) is a transmembrane glycoprotein that is a member of a subfamily of type I receptor tyrosine kinases including EGFR, HER2, HER3, and HER4. The EGFR is constitutively expressed in many normal epithelial tissues, including the skin and hair follicle. Expression of EGFR is also detected in many human cancers including those of the head and neck, colon, and rectum. Cetuximab binds specifically to the EGFR on both normal and tumor cells, and competitively inhibits the binding of epidermal growth factor (EGF) and other ligands, such as...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Sep 24, 2021 Supplement 279 · Efficacy LetterLabel
- Apr 6, 2021 Supplement 280 · Efficacy OrphanLabelLetterReview
- Apr 6, 2021 Supplement 277 · Efficacy LabelLetterReview
- Jul 6, 2012 Supplement 225 · Efficacy LabelLetter
- Nov 7, 2011 Supplement 153 · Efficacy · priority review OrphanLabelLetter
- Oct 2, 2007 Supplement 103 · Efficacy · priority review ReviewLetterLabel
- Mar 1, 2006 Supplement 76 · Efficacy · priority review OrphanLabelLetter
- Mar 1, 2006 Supplement 46 · Efficacy · priority review OrphanLetterLabel
- Feb 12, 2004 Original approval · Type 1 - New Molecular Entity · priority review NovelAccelerated approvalOther Important Information from FDAOtherLabel
1 products under this application
- ERBITUX · CETUXIMAB 100mg/VIAL · VIAL, INTRAVENOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Cetuximab" as an intervention, any sponsor and status, largest first.
- Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon CancerPivotal-lookingCompleted
National Cancer Institute (NCI)NIH
NCT00079274 · 3,397 participants · Start Feb 2004 · Primary completion Nov 2012
Drug: irinotecan hydrochloride; oxaliplatin and 4 more · For: Adenocarcinoma of the Colon; Stage III Colon Cancer
Sites: Anniston, Alabama; Huntsville, Alabama; Mobile, Alabama · 894 sites in all
- Study of Tumor Tissue Testing in Selecting Treatment for Patients With Metastatic or Locally Advanced Colorectal CancerPivotal-lookingCompleted
Medical Research CouncilGovernment (non-federal)
NCT00975897 · 3,240 participants (planned) · Start Jul 2009 · Primary completion Aug 2010
Drug: bevacizumab; cetuximab and 4 more · For: Colorectal Cancer
Sites: Leeds, United Kingdom; Belfast, United Kingdom; Cardiff, United Kingdom
- Combination Chemotherapy With or Without Cetuximab in Treating Patients With Stage III Colon Cancer That Was Completely Removed By SurgeryPivotal-lookingCompleted
Federation Francophone de Cancerologie DigestiveAcademic, hospital or other
NCT00265811 · 2,559 participants · Start Nov 2005 · Primary completion Nov 2009
Drug: Folfox; Cetuximab · For: Colorectal Cancer
Sites: Avignon, France; Caen, France; Libourne, France · 8 sites in all
- Combination Chemotherapy With or Without Cetuximab as First-Line Therapy in Treating Patients With Metastatic Colorectal CancerPivotal-lookingStatus unknown
Velindre NHS TrustGovernment (non-federal)
NCT00182715 · 2,421 participants (planned) · Start Mar 2005 · Primary completion May 2009
Drug: cetuximab; capecitabine and 3 more · For: Colorectal Cancer
Sites: Cork, Ireland; Dublin, Ireland; Galway, Ireland · 82 sites in all
- Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal CancerPivotal-lookingCompleted
Alliance for Clinical Trials in OncologyAcademic, hospital or other
NCT00265850 · 2,334 participants · Start Nov 2005 · Primary completion Feb 2015
Drug: bevacizumab; cetuximab and 2 more · For: Colorectal Cancer
Sites: Mobile, Alabama; Anchorage, Alaska; Fort Smith, Arkansas · 683 sites in all
- Study of Cisplatin/Vinorelbine +/- Cetuximab as First-line Treatment of Advanced Non Small Cell Lung Cancer (FLEX)Pivotal-lookingCompleted
Merck KGaA, Darmstadt, GermanyIndustry
NCT00148798 · 1,861 participants · Start Oct 2004 · Primary completion Jul 2007
Drug: cetuximab + cisplatin + vinorelbine; cisplatin + vinorelbine · For: Non Small Cell Lung Cancer (NSCLC)
Sites: Buenos Aires, Argentina; Córdoba, Argentina; Adelaide, Australia · 118 sites in all
- PETACC-8 miR-31-3p and miR-31-5p Ancillary StudyPivotal-lookingCompleted
IntegraGen SAIndustry
NCT03362684 · 1,808 participants · Start Nov 2005 · Primary completion Nov 2009
Drug: Cetuximab; FOLFOX · For: Colorectal Cancer
- S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung CancerPivotal-lookingTerminated
SWOG Cancer Research NetworkResearch network
NCT00946712 · 1,333 participants · Start Jul 15, 2009 · Primary completion Aug 31, 2017
Drug: Bevacizumab; Carboplatin and 2 more · For: Recurrent Large Cell Lung Carcinoma; Recurrent Lung Adenocarcinoma; Recurrent Squamous Cell Lung Carcinoma and 3 more
Sites: Anniston, Alabama; Mobile, Alabama; Anchorage, Alaska · 798 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- rash2,287
- diarrhoea2,049
- off label use1,923
- nausea1,677
- vomiting1,415
- dyspnoea1,411
- neutropenia1,243
- pyrexia1,137
- malignant neoplasm progression1,136
- infusion related reaction1,113
- dehydration1,106
- fatigue1,096
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 691 |
| 2005 | 1,076 |
| 2006 | 1,313 |
| 2007 | 1,079 |
| 2008 | 1,212 |
| 2009 | 1,407 |
| 2010 | 1,576 |
| 2011 | 1,639 |
| 2012 | 1,656 |
| 2013 | 1,541 |
| 2014 | 1,570 |
| 2015 | 1,412 |
| 2016 | 1,537 |
| 2017 | 1,913 |
| 2018 | 1,472 |
| 2019 | 1,437 |
| 2020 | 1,152 |
| 2021 | 1,237 |
| 2022 | 1,283 |
| 2023 | 1,385 |
| 2024 | 1,371 |
| 2025 | 1,471 |
| 2026 | 1,273 |
Recalls
1 FDA enforcement reports for this application.
Nov 8, 2018 · Class III · Terminated
Labeling: Missing label; potential for missing primary container label on the vial.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Erbitux (Cetuximab)
2024 spending
$6.7M
Beneficiaries
125
684 claims
Per beneficiary
$53,480
$15.40 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $4,866,226 |
| 2021 | $4,928,471 |
| 2022 | $6,811,781 |
| 2023 | $6,921,103 |
| 2024 | $6,684,951 |
Part B: Erbitux (Cetuximab) · HCPCS J9055
2024 spending
$158M
Beneficiaries
3,387
28,555 claims
Per beneficiary
$46,542
2024 ASP limit $74.58 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $144,722,196 |
| 2021 | $138,532,658 |
| 2022 | $153,951,939 |
| 2023 | $155,924,993 |
| 2024 | $157,636,301 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Burtness B, Harrington KJ, Greil R, et al. · Lancet 2019 · Clinical Trial, Phase III, Multicenter Study
- Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer.
Kopetz S, Grothey A, Yaeger R, et al. · N Engl J Med 2019 · Clinical Trial, Phase III, Comparative Study
- Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study.
Tabernero J, Grothey A, Van Cutsem E, et al. · J Clin Oncol 2021 · Clinical Trial, Phase III, Multicenter Study
- Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Vermorken JB, Mesia R, Rivera F, et al. · N Engl J Med 2008 · Clinical Trial, Phase III, Multicenter Study
- Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.
Cunningham D, Humblet Y, Siena S, et al. · N Engl J Med 2004 · Clinical Trial, Comparative Study
- FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.
Heinemann V, von Weikersthal LF, Decker T, et al. · Lancet Oncol 2014 · Clinical Trial, Phase III, Comparative Study
Sponsor: Imclone
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.